DF/HCC Program Affiliation

Lymphoma and Myeloma

Research Abstract

In the laboratory of Dr. Anthony Letai at DFCI, I study resistance to treatment in chronic lymphocytic leukemia (CLL) by utilizing BH3 profiling to investigate the mechanisms underlying stroma-mediated resistance to apoptosis. I am developing an early-phase clinical trial to evaluate pharmacologic combinations that might mitigate stroma-mediated treatment resistance and thereby improve the treatment of CLL. In addition to my laboratory work, I also serve as an attending physician in the DFCI lymphoma group, and as the principal investigator of clinical trials in CLL and non-Hodgkin lymphoma.

Publications

View All Publications